AFWM
CRSP icon

Abich Financial Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Abich Financial Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6
Closed -$324 – 475
2024
Q2 		$324 Hold
6
– – ﹤0.01% 737
2024
Q1 		$409 Buy
+6
New +$430 ﹤0.01% 441

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Abich Financial Wealth Management's CRSP Position: Q3 2024 in Review

Abich Financial Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 6 shares — an estimated $324 sold.

Abich Financial Wealth Management first reported a position in CRSP in Q1 2024 and held it in 2 quarters. The position peaked at $409 in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Abich Financial Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Abich Financial Wealth Management sold 6 CRISPR Therapeutics shares in Q3 2024, an estimated $324.
  • Abich Financial Wealth Management first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 2 quarters.
  • Abich Financial Wealth Management's CRISPR Therapeutics position peaked at $409 in Q1 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Abich Financial Wealth Management's 13F filing for Q3 2024, filed 25 Oct 2024.